TWD 361.5
(-0.14%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 1.98 Billion TWD | 8.08% |
2022 | 1.83 Billion TWD | 25.76% |
2021 | 1.45 Billion TWD | 70.99% |
2020 | 852.36 Million TWD | 46.63% |
2019 | 581.31 Million TWD | -24.81% |
2018 | 773.16 Million TWD | 109.26% |
2017 | 369.47 Million TWD | 55.07% |
2016 | 238.25 Million TWD | 50.86% |
2015 | 157.93 Million TWD | 115.38% |
2014 | 73.33 Million TWD | 51.57% |
2013 | 48.38 Million TWD | 199.6% |
2012 | -48.57 Million TWD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | 995.69 Million TWD | 42.57% |
2024 Q2 | 539.82 Million TWD | -45.78% |
2024 Q3 | 469.59 Million TWD | -13.01% |
2023 Q1 | 413.52 Million TWD | -17.81% |
2023 Q3 | 491.02 Million TWD | 7.58% |
2023 Q2 | 456.43 Million TWD | 10.38% |
2023 Q4 | 698.39 Million TWD | 42.23% |
2023 FY | 1.98 Billion TWD | 8.08% |
2022 Q4 | 503.11 Million TWD | 2.07% |
2022 Q2 | 410.85 Million TWD | -3.57% |
2022 FY | 1.83 Billion TWD | 25.76% |
2022 Q1 | 426.06 Million TWD | -3.34% |
2022 Q3 | 492.91 Million TWD | 19.98% |
2021 Q1 | 258.57 Million TWD | -22.94% |
2021 FY | 1.45 Billion TWD | 70.99% |
2021 Q4 | 440.79 Million TWD | 4.16% |
2021 Q3 | 423.17 Million TWD | 26.35% |
2021 Q2 | 334.91 Million TWD | 29.52% |
2020 Q2 | 167.35 Million TWD | 51.65% |
2020 FY | 852.36 Million TWD | 46.63% |
2020 Q3 | 239.12 Million TWD | 42.89% |
2020 Q1 | 110.35 Million TWD | -42.47% |
2020 Q4 | 335.53 Million TWD | 40.32% |
2019 Q3 | 141.06 Million TWD | 29.25% |
2019 Q2 | 109.14 Million TWD | -21.65% |
2019 Q1 | 139.29 Million TWD | -35.98% |
2019 FY | 581.31 Million TWD | -24.81% |
2019 Q4 | 191.81 Million TWD | 35.97% |
2018 Q4 | 217.59 Million TWD | -11.27% |
2018 FY | 773.16 Million TWD | 109.26% |
2018 Q3 | 245.23 Million TWD | 41.57% |
2018 Q2 | 173.22 Million TWD | 14.01% |
2018 Q1 | 151.93 Million TWD | 59.87% |
2017 Q3 | 95.03 Million TWD | 14.03% |
2017 Q1 | 83.34 Million TWD | 19.9% |
2017 FY | 369.47 Million TWD | 55.07% |
2017 Q4 | 95.03 Million TWD | 0.0% |
2017 Q2 | 83.34 Million TWD | 0.0% |
2016 Q1 | 48.92 Million TWD | 35.94% |
2016 Q2 | 48.92 Million TWD | 0.0% |
2016 Q3 | 69.5 Million TWD | 42.08% |
2016 FY | 238.25 Million TWD | 50.86% |
2016 Q4 | 69.5 Million TWD | 0.0% |
2015 Q4 | 35.98 Million TWD | 0.0% |
2015 Q2 | 32.41 Million TWD | 0.0% |
2015 Q3 | 35.98 Million TWD | 11.01% |
2015 Q1 | 32.41 Million TWD | 50.94% |
2015 FY | 157.93 Million TWD | 115.38% |
2014 Q2 | 8.23 Million TWD | 0.0% |
2014 Q3 | 21.47 Million TWD | 160.95% |
2014 FY | 73.33 Million TWD | 51.57% |
2014 Q4 | 21.47 Million TWD | 0.0% |
2014 Q1 | 8.23 Million TWD | 629.33% |
2013 Q2 | 13.89 Million TWD | 0.0% |
2013 Q4 | 1.12 Million TWD | 0.0% |
2013 Q1 | 13.89 Million TWD | 0.0% |
2013 FY | 48.38 Million TWD | 199.6% |
2013 Q3 | 1.12 Million TWD | -91.88% |
2012 FY | -48.57 Million TWD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Nang Kuang Pharmaceutical Co., Ltd. | 259.91 Million TWD | -662.227% |
Maxigen Biotech Inc. | 149.85 Million TWD | -1222.063% |
SciVision Biotech Inc. | 199.63 Million TWD | -892.352% |
Bionime Corporation | -13.33 Million TWD | 14952.02% |
Visco Vision Inc. | 334.7 Million TWD | -491.894% |